Institutional members access full text with Ovid®

Share this article on:

Thyroid cancer management: from a suspicious nodule to targeted therapy

Perri, Francescoa; Giordano, Antonioe; Pisconti, Salvatorea; Ionna, Francob; Chiofalo, Maria, G.c; Longo, Francescob; Leopardo, Davided; Della Vittoria Scarpati, Giuseppinaa; Pezzullo, Lucianoc

doi: 10.1097/CAD.0000000000000617
Review Article

Thyroid nodules are very common, and their frequency is four to five times higher in women than in men. Most of them are benign, with only a very little percentage revealing a malignant neoplasm. About 50% of thyroid nodules are detected by self-palpation of neck, whereas the other 50% are diagnosed by neck ultrasonography and following fine-needle aspiration. Management of thyroid nodules is very difficult, because benign nodules are prevalent, whereas thyroid carcinoma is uncommon, representing only 1% of all malignancies. A standard diagnostic approach is represented by ‘first-level’ exams, consisting in neck ultrasonography and serum thyroid-stimulating hormone measurement, followed, only for nodules that are suspicious of malignancy, by ‘second-level’ exams, consisting of fine-needle aspiration and mutational test, which does detect particular DNA mutations present only in malignant cells. In this review, we will analyze the genetics of thyroid cancer and its heterogeneity, and we will briefly describe the current available diagnostic and therapeutic approaches.

aMedical Oncology Unit, POC SS Annunziata, Taranto

bDepartment of Head and Neck Surgery, Otolaryngology Unit

cOtolaryngology Unit, Department of Thyroid Surgery, National Tumor Institute of Naples, Foundation G Pascale, Naples

dMedical Oncology Unit, Hospital of Caserta, Caserta, Italy

eDepartment of Medicine, Division of Hematology & Oncology, Medical University of South Carolina, Charleston, South Carolina, USA

Correspondence to Francesco Perri, MD, Medical Oncology Unit, POC SS Annunziata, Taranto 74100, Italy Tel: +34 89 145 086; fax: +34 99 458 5813; e-mail: francesco.perri80@alice.it

Received November 23, 2017

Accepted February 20, 2018

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.